KR20160055818A - 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절 - Google Patents
암 및 바이러스 감염을 치료하기 위한 면역수용체 조절 Download PDFInfo
- Publication number
- KR20160055818A KR20160055818A KR1020167007431A KR20167007431A KR20160055818A KR 20160055818 A KR20160055818 A KR 20160055818A KR 1020167007431 A KR1020167007431 A KR 1020167007431A KR 20167007431 A KR20167007431 A KR 20167007431A KR 20160055818 A KR20160055818 A KR 20160055818A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- mammal
- inhibitor
- antibody
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 42
- 201000011510 cancer Diseases 0.000 title claims abstract description 20
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 9
- 230000009385 viral infection Effects 0.000 title claims abstract description 9
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims abstract description 165
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims abstract description 165
- 238000000034 method Methods 0.000 claims abstract description 63
- 241000124008 Mammalia Species 0.000 claims abstract description 52
- 239000003112 inhibitor Substances 0.000 claims abstract description 35
- 230000005764 inhibitory process Effects 0.000 claims abstract description 33
- 206010027476 Metastases Diseases 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 24
- 230000009401 metastasis Effects 0.000 claims abstract description 24
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 22
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 19
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 19
- 230000001900 immune effect Effects 0.000 claims abstract description 15
- 238000012216 screening Methods 0.000 claims abstract description 10
- 230000037451 immune surveillance Effects 0.000 claims abstract description 9
- 230000002147 killing effect Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 82
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 39
- 108010048507 poliovirus receptor Proteins 0.000 claims description 39
- 230000027455 binding Effects 0.000 claims description 31
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 30
- 102000004127 Cytokines Human genes 0.000 claims description 29
- 108090000695 Cytokines Proteins 0.000 claims description 29
- 102000019034 Chemokines Human genes 0.000 claims description 16
- 108010012236 Chemokines Proteins 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 15
- 230000028327 secretion Effects 0.000 claims description 10
- 108010074328 Interferon-gamma Proteins 0.000 claims description 6
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000004068 intracellular signaling Effects 0.000 claims description 6
- 102000008070 Interferon-gamma Human genes 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229960003130 interferon gamma Drugs 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 3
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 abstract description 9
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 9
- 230000002708 enhancing effect Effects 0.000 abstract description 7
- 241000699670 Mus sp. Species 0.000 description 56
- 210000000822 natural killer cell Anatomy 0.000 description 52
- 102100038077 CD226 antigen Human genes 0.000 description 35
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 35
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 28
- 210000004072 lung Anatomy 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 20
- 230000001404 mediated effect Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229960004679 doxorubicin Drugs 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000006023 anti-tumor response Effects 0.000 description 12
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 11
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 229940045513 CTLA4 antagonist Drugs 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 102000002356 Nectin Human genes 0.000 description 4
- 108060005251 Nectin Proteins 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000581 natural killer T-cell Anatomy 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000007781 signaling event Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 101100098678 Homo sapiens CD96 gene Proteins 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000002698 KIR Receptors Human genes 0.000 description 3
- 108010043610 KIR Receptors Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- -1 NCR Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 230000005746 immune checkpoint blockade Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 2
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 description 2
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091008877 NK cell receptors Proteins 0.000 description 2
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 2
- 102100035488 Nectin-2 Human genes 0.000 description 2
- 102100035487 Nectin-3 Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102000014400 SH2 domains Human genes 0.000 description 2
- 108050003452 SH2 domains Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 2
- 230000010001 cellular homeostasis Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Substances OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 101000878581 Aplysia californica Feeding circuit activating peptides Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 101100181099 Mus musculus Klra1 gene Proteins 0.000 description 1
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 101150065403 NECTIN2 gene Proteins 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- 102100023064 Nectin-1 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 101000916532 Rattus norvegicus Zinc finger and BTB domain-containing protein 38 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000010380 label transfer Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013903189 | 2013-08-22 | ||
| AU2013903189A AU2013903189A0 (en) | 2013-08-22 | Immunomodulator | |
| PCT/AU2013/001132 WO2015024042A1 (en) | 2013-08-22 | 2013-10-03 | Immunoreceptor modulation for treating cancer and viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160055818A true KR20160055818A (ko) | 2016-05-18 |
Family
ID=52482821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167007431A Ceased KR20160055818A (ko) | 2013-08-22 | 2013-10-03 | 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160200814A1 (enExample) |
| EP (1) | EP3036255A4 (enExample) |
| JP (1) | JP2016530267A (enExample) |
| KR (1) | KR20160055818A (enExample) |
| CN (1) | CN105636983A (enExample) |
| AU (1) | AU2013398294A1 (enExample) |
| BR (1) | BR112016003528A8 (enExample) |
| CA (1) | CA2921772A1 (enExample) |
| HK (1) | HK1225395A1 (enExample) |
| MX (1) | MX2016002265A (enExample) |
| SG (1) | SG11201601285XA (enExample) |
| WO (1) | WO2015024042A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| JP7118072B2 (ja) * | 2017-01-06 | 2022-08-15 | イミュニティーバイオ インコーポレイテッド | Ｃｄ９６／ｔｉｇｉｔ発現が低下した遺伝子改変型ｎｋ－９２細胞 |
| US20230192845A1 (en) * | 2017-08-11 | 2023-06-22 | Blink Biomedical Sas | Cd96-binding agents as immunomodulators |
| CN110914304B (zh) * | 2017-11-10 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | Cd96抗体、其抗原结合片段及医药用途 |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| PH12022550671A1 (en) * | 2019-09-27 | 2023-05-29 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
| EP4052727A4 (en) * | 2019-10-30 | 2023-12-20 | University of Tsukuba | IMMUNE RESPONSE INHIBITOR |
| CN116377061B (zh) * | 2022-11-28 | 2024-01-16 | 中山大学孙逸仙纪念医院 | 乳腺癌新辅助化疗耐药标志物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1481993A1 (en) * | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| CN1777622A (zh) * | 2003-02-24 | 2006-05-24 | 施里昂药品股份公司 | 脊髓灰质炎病毒受体功能的调节 |
| WO2005107799A1 (ja) * | 2004-05-06 | 2005-11-17 | Eisai R & D Management Co., Ltd. | 抗Necl-5抗体を有効成分として含む癌治療剤 |
| US7767410B2 (en) * | 2006-12-07 | 2010-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| MX2010011088A (es) * | 2008-04-09 | 2010-11-05 | Genentech Inc | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. |
| WO2011057216A1 (en) * | 2009-11-06 | 2011-05-12 | The Pennsylvania State Research Foundation | Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo |
| CN102204901A (zh) * | 2010-03-30 | 2011-10-05 | 中国科学院上海生命科学研究院 | 调节免疫分子的试剂和方法 |
| ES2967538T3 (es) * | 2013-08-22 | 2024-04-30 | Council Queensland Inst Medical Res | Modulación del inmunorreceptor para el tratamiento del cáncer e infecciones virales |
-
2013
- 2013-10-03 BR BR112016003528A patent/BR112016003528A8/pt not_active IP Right Cessation
- 2013-10-03 HK HK16113672.0A patent/HK1225395A1/zh unknown
- 2013-10-03 US US14/913,347 patent/US20160200814A1/en not_active Abandoned
- 2013-10-03 CN CN201380079711.6A patent/CN105636983A/zh active Pending
- 2013-10-03 JP JP2016535268A patent/JP2016530267A/ja active Pending
- 2013-10-03 KR KR1020167007431A patent/KR20160055818A/ko not_active Ceased
- 2013-10-03 MX MX2016002265A patent/MX2016002265A/es unknown
- 2013-10-03 WO PCT/AU2013/001132 patent/WO2015024042A1/en not_active Ceased
- 2013-10-03 CA CA2921772A patent/CA2921772A1/en not_active Abandoned
- 2013-10-03 EP EP13891700.0A patent/EP3036255A4/en not_active Withdrawn
- 2013-10-03 AU AU2013398294A patent/AU2013398294A1/en not_active Abandoned
- 2013-10-03 SG SG11201601285XA patent/SG11201601285XA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1225395A1 (zh) | 2017-09-08 |
| MX2016002265A (es) | 2016-12-16 |
| SG11201601285XA (en) | 2016-03-30 |
| EP3036255A1 (en) | 2016-06-29 |
| US20160200814A1 (en) | 2016-07-14 |
| EP3036255A4 (en) | 2017-03-22 |
| WO2015024042A1 (en) | 2015-02-26 |
| AU2013398294A1 (en) | 2016-03-17 |
| CN105636983A (zh) | 2016-06-01 |
| CA2921772A1 (en) | 2015-02-26 |
| JP2016530267A (ja) | 2016-09-29 |
| BR112016003528A8 (pt) | 2018-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210047403A1 (en) | Immunoreceptor modulation for treating cancer and viral infections | |
| KR20160055818A (ko) | 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절 | |
| Rosen et al. | Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells | |
| AU2019377854A1 (en) | Methods and combinations for treatment and T cell modulation | |
| CA2988119A1 (en) | Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy | |
| Akkaya et al. | Dissection of agonistic and blocking effects of CD200 receptor antibodies | |
| IL320293A (en) | Therapeutic agent for T cell malignancies | |
| AU2014308552B2 (en) | Immunoreceptor modulation for treating cancer and viral infections | |
| Yu et al. | Progranulin facilitates the increase of platelet count in immune thrombocytopenia | |
| Saha | Targeting the TIGIT/CD226/CD96 signaling Axis using the IgV domain of PVR | |
| Cantoni et al. | Inhibitory and Activating Natural Killer Receptors in Humans: A Historical Overview | |
| US20250339464A1 (en) | Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof | |
| WO2025220689A1 (ja) | Ｔ細胞機能不全のｔ細胞性腫瘍患者に有効な二重特異性抗体 | |
| JP7280586B2 (ja) | 樹状細胞の成熟抑制剤及び成熟抑制方法、並びに医薬組成物 | |
| Garcia et al. | SIRPo/CD172a Regulates Eosinophil Homeostasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160321 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180820 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20191118 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20200214 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20191118 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |